Conclusion: Taken together, our findings revealed that IL-1β-induced elevation of lncRNA CHRF aggravated NSCLC through modulation of miR-489/Myd88 axis, which provides a novel direction for NSCLC therapy development. The gene discussed is MYD88; the disease is non-small cell lung carcinoma.